News & Events

The Cancer Grand Challenges Program will award $100 million to four interdisciplinary teams from around the world to solve some of the toughest challenges in cancer research. Each team will receive $25 million over 5 years.

Results from the NCI-supported ANCHOR study show that treating anal precancerous growths known as high-grade squamous intraepithelial lesions, or HSIL, reduces the chance that anal cancer will develop by more than half.

From 1999—2019, US rates of cancer death fell among Black people. Yet, in 2019, their rates remained higher than those of other racial and ethnic groups.

Deaths from uterine cancer are rising in the United States, and are highest among non-Hispanic Black women, according to a new study led by researchers at NCI, part of the National Institutes of Health. The higher death rates are related to the rising incidence of aggressive subtypes of uterine cancer.

Norman E. “Ned” Sharpless, M.D., announces his decision to step down as NCI director, a position he has held since 2017. NCI Principal Deputy Director Douglas R. Lowy, M.D., will serve as NCI’s acting director beginning April 30, 2022.

The Molecular Characterization Initiative will offer state-of-the-art diagnoses to children, adolescents, and young adults with central nervous system tumors.

NCI researchers have found unique expression profiles in 50 genes that help identify rare anti-tumor lymphocytes that can infiltrate and help defeat metastatic solid epithelial tumors.

NCI researchers have shown that an experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer who have exhausted all other treatment options.

NCI researchers have found that a diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome. The new findings come from an analysis of people with melanoma and mouse models of the disease.

A Children’s Oncology Group trial shows that the combination of all-trans retinoic acid and arsenic trioxide is highly effective in children with acute promyelocytic leukemia. The therapy avoids or minimizes the use of conventional chemotherapy.